Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 6/2012

01-12-2012

Preoperative Echocardiographic-Defined Moderate–Severe Pulmonary Hypertension Predicts Prolonged Duration of Mechanical Ventilation Following Lung Transplantation for Patients with COPD

Authors: Jeremy P. Wrobel, Bruce R. Thompson, Gregory I. Snell, Trevor J. Williams

Published in: Lung | Issue 6/2012

Login to get access

Abstract

Purpose

Recent studies have suggested that pretransplant secondary pulmonary hypertension (PHT) may be associated with worse outcomes following lung transplantation. We sought to determine whether COPD patients with secondary PHT have inferior intensive care outcomes following lung transplantation.

Methods

This is a single-center, retrospective analysis of all lung transplant recipients between 2000 and 2009 for a primary diagnosis of COPD. Patients were stratified a priori into three pulmonary arterial pressure groups based on right ventricular systolic pressure (RVSP): no PHT (RVSP < 35 mmHg), mild PHT (35 ≤ RVSP < 45 mmHg), and moderate–severe PHT (RVSP ≥ 45 mmHg). Outcome measures were duration of mechanical ventilation, intensive care unit (ICU) length of stay, and PaO2/fraction inspired oxygen (PaO2/FIO2) ratio at 24 h posttransplantation.

Results

A total of 46 COPD lung transplant recipients with documented pretransplant RVSP were included in the analysis, including 18 with no PHT, 20 with mild PHT, and eight with moderate–severe PHT. There were no differences in baseline demographics between the three pulmonary arterial pressure groups. The presence of moderate–severe PHT predicted increased duration of mechanical ventilation (P = 0.024), worse PaO2/FIO2 ratio at 24 h (P = 0.027), and a trend toward increased ICU length of stay (P = 0.055). RVSP was the strongest risk factor for duration of mechanical ventilation and ICU length of stay. There was no difference in 1-year survival amongst the three pulmonary arterial pressure groups.

Conclusions

Preoperative moderate–severe PHT predicts prolonged duration of mechanical ventilation following lung transplantation in COPD subjects.
Literature
1.
Chatila WM, Furukawa S, Gaughan JP et al (2003) Respiratory failure after lung transplantation. Chest 123(1):165–173PubMedCrossRef
2.
Christie JD, Kotloff RM, Pochettino A et al (2003) Clinical risk factors for primary graft failure following lung transplantation. Chest 124(4):1232–1241PubMedCrossRef
3.
Whitson BA, Nath DS, Johnson AC et al (2006) Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 131(1):73–80PubMedCrossRef
4.
Kuntz CL, Hadjiliadis D, Ahya VN et al (2009) Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 23(6):819–830PubMedCrossRef
5.
Lee JC, Christie JD, Keshavjee S (2010) Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. Semin Respir Crit Care Med 31(2):161–171PubMedCrossRef
6.
Barr ML, Kawut SM, Whelan TP et al (2005) Report of the ISHLT working group on primary lung graft dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 24(10):1468–1482PubMedCrossRef
7.
Bando K, Keenan RJ, Paradis IL et al (1994) Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 58(5):1336–1342PubMedCrossRef
8.
Lee KH, Martich GD, Boujoukos AJ et al (1996) Predicting ICU length of stay following single lung transplantation. Chest 110(4):1014–1017PubMedCrossRef
9.
Fang A, Studer S, Kawut SM et al (2011) Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 139(4):782–787PubMedCrossRef
10.
Whelan TP, Dunitz JM, Kelly RF et al (2005) Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 24(9):1269–1274PubMedCrossRef
11.
Prekker ME, Nath DS, Walker AR et al (2006) Validation of the proposed international society for heart and lung transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 25(4):371–378PubMedCrossRef
12.
Sullivan VN, Whitson BA, Radosevich DM et al (2006) Elevated pulmonary artery pressure predicts development of severe primary graft dysfunction in paired single lung transplant recipients. J Heart Lung Transplant 25(2S):S47CrossRef
13.
Christie JD, Bavaria JE, Palevsky HI et al (1998) Primary graft failure following lung transplantation. Chest 114(1):51–60PubMedCrossRef
14.
Huerd SS, Hodges TN, Grover FL et al (2000) Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg 119(3):458–465PubMedCrossRef
15.
Fitton TP, Kosowski TR, Barreiro CJ et al (2005) Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 24(9):1254–1259PubMedCrossRef
16.
Omari MK, Smith SA, Jacobsen G et al (2011) Effect of pulmonary hypertension in patients with end-stage lung disease on posttransplantation outcomes. Transplant Proc 43(5):1881–1886PubMedCrossRef
17.
Andersen KH, Iversen M, Kjaergaard J et al (2012) Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 31(4):373–380PubMedCrossRef
18.
Christie JD, Edwards LB, Kucheryavaya AY et al (2010) The registry of the international society for heart and lung transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 29(10):1104–1118PubMedCrossRef
19.
Thabut G, Dauriat G, Stern JB et al (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127(5):1531–1536PubMedCrossRef
20.
Badesch DB, Champion HC, Sanchez MAG et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(1, Supplement 1):S55–S66PubMedCrossRef
21.
22.
Mutlu GM, Factor P (2000) Complications of mechanical ventilation. Respir Care Clin N Am 6(2):213–252PubMedCrossRef
23.
Feng Y, Amoateng-Adjepong Y, Kaufman D et al (2009) Age, duration of mechanical ventilation, and outcomes of patients who are critically ill. Chest 136(3):759–764PubMedCrossRef
24.
Gruenberg DA, Shelton W, Rose SL et al (2006) Factors influencing length of stay in the intensive care unit. Am J Crit Care 15(5):502–509PubMed
25.
Conte JV, Borja MJ, Patel CB et al (2001) Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 72(5):1673–1679PubMedCrossRef
26.
Boujoukos AJ, Martich GD, Vega JD et al (1997) Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema. J Heart Lung Transplant 16(4):439–448PubMed
27.
Arcasoy SM, Fisher A, Hachem RR et al (2005) Report of the ISHLT working group on primary lung graft dysfunction part V: predictors and outcomes. J Heart Lung Transplant 24(10):1483–1488PubMedCrossRef
28.
Oto T, Levvey BJ, Pilcher DV et al (2005) Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 130(1):180–186PubMedCrossRef
29.
Christie JD, Sager JS, Kimmel SE et al (2005) Impact of primary graft failure on outcomes following lung transplantation. Chest 127(1):161–165PubMedCrossRef
30.
Fiser SM, Tribble CG, Long SM et al (2002) Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 73(4):1041–1047PubMedCrossRef
31.
Fisher AJ, Wardle J, Dark JH et al (2002) Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 21(11):1206–1212PubMedCrossRef
32.
Whitson BA, Prekker ME, Herrington CS et al (2007) Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 26(10):1004–1011PubMedCrossRef
33.
Oto T, Levvey BJ, Snell GI (2007) Potential refinements of the international society for heart and lung transplantation primary graft dysfunction grading system. J Heart Lung Transplant 26(5):431–436PubMedCrossRef
34.
Christie JD, Edwards LB, Kucheryavaya AY et al (2011) The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report-2011. J Heart Lung Transplant 30(10):1104–1122PubMedCrossRef
35.
Marasco SF, Bailey M, McGlade D et al (2011) Effect of donor preservation solution and survival in lung transplantation. J Heart Lung Transplant 30(4):414–419PubMedCrossRef
36.
de Perrot M, Bonser RS, Dark J et al (2005) Report of the ISHLT working group on primary lung graft dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 24(10):1460–1467PubMedCrossRef
37.
Cassivi SD, Meyers BF, Battafarano RJ et al (2002) Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 74(5):1663–1669PubMedCrossRef
38.
Szeto WY, Kreisel D, Karakousis GC et al (2002) Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. J Thorac Cardiovasc Surg 124(2):241–249PubMedCrossRef
39.
de Perrot M, Liu M, Waddell TK et al (2003) Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167(4):490–511PubMedCrossRef
40.
Christie JD, Robinson N, Ware LB et al (2007) Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 175(1):69–74PubMedCrossRef
41.
Covarrubias M, Ware LB, Kawut SM et al (2007) Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 7(11):2573–2578PubMedCrossRef
42.
Kawut SM, Okun J, Shimbo D et al (2009) Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 136(1):237–244PubMedCrossRef
43.
Thabut G, Ravaud P, Christie JD et al (2008) Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177(10):1156–1163PubMedCrossRef
44.
Arcasoy SM, Christie JD, Ferrari VA et al (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167(5):735–740PubMedCrossRef
45.
Fisher MR, Criner GJ, Fishman AP et al (2007) Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 30(5):914–921PubMedCrossRef
46.
Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621PubMedCrossRef
47.
Hoeper MM, Barberà JA, Channick RN et al (2009) Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54(1):S85–S96PubMedCrossRef
48.
Stone AC, Machan JT, Mazer J et al (2011) Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 189(3):207–212PubMedCrossRef
Metadata
Title
Preoperative Echocardiographic-Defined Moderate–Severe Pulmonary Hypertension Predicts Prolonged Duration of Mechanical Ventilation Following Lung Transplantation for Patients with COPD
Authors
Jeremy P. Wrobel
Bruce R. Thompson
Gregory I. Snell
Trevor J. Williams
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Lung / Issue 6/2012
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-012-9423-7

Other articles of this Issue 6/2012

Lung 6/2012 Go to the issue

OriginalPaper

High-Frequency Oscillatory Ventilation in Pediatric Acute Hypoxemic Respiratory Failure: Disease-Specific Morbidity Survival Analysis

OriginalPaper

Effect of Cigarette Smoke Extract on Insulin Transport in Alveolar Epithelial Cell Line A549

OriginalPaper

Intragastric Balloon for the Treatment of Obesity: Evaluation of Pulmonary Function Over a 3-Month Period

Letter to the Editor

Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments

OriginalPaper

Overwhelming Support Among Urban Irish COPD Patients for Lung Cancer Screening by Low-Dose CT Scan

Letter to the Editor

Reporting Genetic Association Studies: The Roadblocks and Guiding Rules for Robust Results
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits